SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 7.72 |
| Enterprise Value ($M) | 0.15 |
| Book Value ($M) | 11.29 |
| Book Value / Share | 4.45 |
| Price / Book | 0.68 |
| NCAV ($M) | 5.94 |
| NCAV / Share | 2.34 |
| Price / NCAV | 1.30 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.47 |
| Return on Assets (ROA) | -0.46 |
| Return on Equity (ROE) | -1.34 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.85 |
| Current Ratio | 3.85 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 8.02 |
| Assets | 13.37 |
| Liabilities | 2.09 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -9.65 |
| Net Income | -5.26 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -21.25 |
| Cash from Investing | 10.40 |
| Cash from Financing | 5.02 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Tyndall Capital Partners L P | 6.70 | 35.18 | |
| 13G/A | Artal International S.C.A. | 5.70 | -95.00 | |
| 13G/A | Fmr Llc | 6.66 | ||
| 13G/A | Slate Path Capital LP | 14.60 | ||
| 13D/A | Hecht Peter M | 62.19 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 300 | 597 | 50.25 | |
| 218 | 431 | 50.58 | |
| 166 | 1,275 | 13.02 | |
| 33 | 110 | 30.00 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CUE – Cue Biopharma, Inc. | CVKD – Cadrenal Therapeutics, Inc. |
| CYCC – Cyclacel Pharmaceuticals, Inc. | CYRX – Cryoport, Inc. |
| CYTH – Cyclo Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io